Allogeneic tumor enhancement by levamisole, a new immunostimulatory compound: Studies on cell-mediated immunity and humoral antibody response

A. Mantovani, F. Spreafico

Research output: Contribution to journalArticle

Abstract

C3H mice transplanted with the incompatible L1210 leukemia exhibited progressive tumor takes in a high percentage of cases when treated with the same course of the chemical immunostimulant levamisole which could induce a marked rise in the immune response towards allogeneic erythrocytes. Investigations of the specific antitumoral immune reactivity revealed in progressor mice a depression of cell-mediated immunity and serum cytotoxic antibodies and an increased serum blocking activity. The relevance of these immunological modifications to enhanced tumor growth and the possible mechanisms of action of the immunostimulant are discussed in this paper.

Original languageEnglish
Pages (from-to)537-544
Number of pages8
JournalEuropean Journal of Cancer (1965)
Volume11
Issue number8
DOIs
Publication statusPublished - 1975

Fingerprint

Immunologic Adjuvants
Levamisole
Cellular Immunity
Antibody Formation
Leukemia L1210
Inbred C3H Mouse
Serum
Neoplasms
Erythrocytes
Antibodies
Growth

ASJC Scopus subject areas

  • Oncology

Cite this

@article{b6ba8b31f0414f82beb857987ccf7347,
title = "Allogeneic tumor enhancement by levamisole, a new immunostimulatory compound: Studies on cell-mediated immunity and humoral antibody response",
abstract = "C3H mice transplanted with the incompatible L1210 leukemia exhibited progressive tumor takes in a high percentage of cases when treated with the same course of the chemical immunostimulant levamisole which could induce a marked rise in the immune response towards allogeneic erythrocytes. Investigations of the specific antitumoral immune reactivity revealed in progressor mice a depression of cell-mediated immunity and serum cytotoxic antibodies and an increased serum blocking activity. The relevance of these immunological modifications to enhanced tumor growth and the possible mechanisms of action of the immunostimulant are discussed in this paper.",
author = "A. Mantovani and F. Spreafico",
year = "1975",
doi = "10.1016/0014-2964(75)90125-5",
language = "English",
volume = "11",
pages = "537--544",
journal = "European Journal of Cancer",
issn = "0014-2964",
publisher = "Elsevier Ltd",
number = "8",

}

TY - JOUR

T1 - Allogeneic tumor enhancement by levamisole, a new immunostimulatory compound

T2 - Studies on cell-mediated immunity and humoral antibody response

AU - Mantovani, A.

AU - Spreafico, F.

PY - 1975

Y1 - 1975

N2 - C3H mice transplanted with the incompatible L1210 leukemia exhibited progressive tumor takes in a high percentage of cases when treated with the same course of the chemical immunostimulant levamisole which could induce a marked rise in the immune response towards allogeneic erythrocytes. Investigations of the specific antitumoral immune reactivity revealed in progressor mice a depression of cell-mediated immunity and serum cytotoxic antibodies and an increased serum blocking activity. The relevance of these immunological modifications to enhanced tumor growth and the possible mechanisms of action of the immunostimulant are discussed in this paper.

AB - C3H mice transplanted with the incompatible L1210 leukemia exhibited progressive tumor takes in a high percentage of cases when treated with the same course of the chemical immunostimulant levamisole which could induce a marked rise in the immune response towards allogeneic erythrocytes. Investigations of the specific antitumoral immune reactivity revealed in progressor mice a depression of cell-mediated immunity and serum cytotoxic antibodies and an increased serum blocking activity. The relevance of these immunological modifications to enhanced tumor growth and the possible mechanisms of action of the immunostimulant are discussed in this paper.

UR - http://www.scopus.com/inward/record.url?scp=0016713622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016713622&partnerID=8YFLogxK

U2 - 10.1016/0014-2964(75)90125-5

DO - 10.1016/0014-2964(75)90125-5

M3 - Article

C2 - 1222761

AN - SCOPUS:0016713622

VL - 11

SP - 537

EP - 544

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0014-2964

IS - 8

ER -